{
    "brief_title": "OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk",
    "phase": "Phase 4",
    "drugs": "['Ovarian function suppression with endocrine treatments']",
    "drugs_list": [
        "Ovarian function suppression with endocrine treatments"
    ],
    "diseases": "['Breast Cancer', 'Estrogen Receptor Positive Tumor', 'HER2-negative Breast Cancer', 'Premenopausal Breast Cancer', 'Node-positive Breast Cancer']",
    "diseases_list": [
        "Breast Cancer",
        "Estrogen Receptor Positive Tumor",
        "HER2-negative Breast Cancer",
        "Premenopausal Breast Cancer",
        "Node-positive Breast Cancer"
    ],
    "enrollment": "418.0",
    "inclusion_criteria": "inclusion criteria: \n\n ER+HER2- breast cancer \n\n Premenopausal and age <=50 \n\n T1 or T2 \n\n N1 including micrometastasis \n\n Genomic Low Risk by OncoFREE test\u00ae (1-20) \n\n ",
    "exclusion_criteria": ": \n\n Postmenopausal women \n\n ER-negative breast cancer",
    "brief_summary": "Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE\u00ae).~In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.",
    "NCT_ID": "NCT05333328"
}